How should recurrent Clostridioides difficile infection be treated?

Treatment of Recurrent Clostridioides difficile Infection

For recurrent CDI, use oral fidaxomicin 200 mg twice daily for 10 days as first-line therapy, or alternatively use oral vancomycin in a tapered and pulsed regimen; after two or more recurrences (third episode), strongly consider fecal microbiota transplantation. 1, 2

First Recurrence (Second Episode)

The 2021 IDSA/SHEA focused update provides the most current evidence-based approach 2:

Preferred options:

• Fidaxomicin 200 mg twice daily for 10 days - This is now favored based on pooled analysis showing increased sustained response at 30 days (RR: 1.27; 95% CI: 1.05–1.54) compared to vancomycin 2
• Vancomycin tapered and pulsed regimen - Example: 125 mg four times daily for 10-14 days, then twice daily for 1 week, once daily for 1 week, then every 2-3 days for 2-8 weeks 1

Alternative if metronidazole was used initially:

• Standard vancomycin 125 mg four times daily for 10 days 1

The key distinction here is that fidaxomicin demonstrates superior sustained response rates and lower recurrence compared to standard vancomycin courses, though both achieve similar initial clinical cure rates 2. The extended-pulsed fidaxomicin regimen (used in the EXTEND trial) showed particularly impressive results with only 2% recurrence at day 40 versus 17% with vancomycin 2.

Second or Subsequent Recurrence (Third+ Episode)

Multiple antibiotic options exist 1:

• Vancomycin tapered and pulsed regimen (as above)
• Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days
• Fidaxomicin 200 mg twice daily for 10 days
• Extended-pulsed fidaxomicin regimen (200 mg twice daily for 5 days, then once daily on alternate days for days 7-25) 3

Fecal Microbiota Transplantation - The Game Changer

FMT is strongly recommended after appropriate antibiotic treatment for at least 2 recurrences (meaning 3 total CDI episodes) 1. This represents a strong recommendation with moderate quality evidence - one of the highest-rated recommendations in the guidelines 1.

The evidence is compelling:

• Success rates of 70-92% across multiple RCTs 3, 4
• Significantly superior to vancomycin alone (81% cure with FMT vs 31% with vancomycin in landmark 2013 trial) 5
• The 2024 British guidelines now recommend offering FMT to all patients with two or more recurrences 4

FDA-approved standardized microbiome therapies are now available 6, 7:

• Fecal microbiota spores, live-brpk (Vowst) - oral formulation showing 12% recurrence vs 40% placebo in ECOSPOR III trial
• Fecal microbiota, live-jslm (Rebyota) - RBX2660 demonstrating 70.6% efficacy vs 57.5% placebo in PUNCH CD3 trial

These standardized products address the heterogeneity concerns with traditional FMT while maintaining efficacy 6.

Key Clinical Considerations

Timing matters: FMT should be preceded by at least 10 days of appropriate antibiotic therapy for the acute infection 4. The British guidelines specify that FMT can be considered earlier (even at first recurrence) for severe, fulminant, or complicated CDI not responding to antibiotics 4.

Route of administration: Frozen FMT is preferred over fresh preparations, and can be delivered via colonoscopy, upper endoscopy, or oral capsules 4. Universal donors are preferred over related donors 4.

Common pitfall: Do not use metronidazole for recurrent CDI - it is no longer recommended and shows inferior outcomes 1, 8, 9. The evidence clearly demonstrates vancomycin's superiority in severe disease and recurrent infections 5.

Special Populations

For patients with inflammatory bowel disease and recurrent CDI: The same treatment principles apply, though these patients face higher recurrence risk 10. Microbiome-based therapies should be offered after at least one recurrence 10.

For patients requiring ongoing systemic antibiotics: Consider suppressive vancomycin 125 mg daily as secondary prophylaxis, particularly in high-risk patients who cannot receive FMT 7. However, routine prophylactic vancomycin during antibiotic courses is not generally advised 1.

Algorithm Summary

1. First recurrence: Fidaxomicin 10 days OR vancomycin taper/pulse
2. Second recurrence: Same antibiotic options PLUS strongly consider FMT
3. Third+ recurrence: FMT is the preferred strategy after antibiotic treatment
4. Refractory cases: Multi-dose FMT, consider suppressive vancomycin if FMT unavailable/failed

Critical point: The shift toward microbiome restoration represents the most significant advance in recurrent CDI management. After multiple antibiotic courses fail, continuing the same approach yields diminishing returns - FMT addresses the underlying dysbiosis that perpetuates recurrence 6, 11, 12.